Ake­bia no­ti­fies SEC it will be late fil­ing Q2 earn­ings; Sur­rozen cuts two ear­ly pro­grams

Ake­bia Ther­a­peu­tics an­nounced Fri­day that it will be late fil­ing its sec­ond-quar­ter earn­ings re­port due to “cer­tain ac­count­ing er­rors” around its on­ly ap­proved drug, Au­ryx­ia.

The biotech said that the er­rors re­late to record­ing and re­port­ing “re­turn re­serves” for the drug from 2020 in­to the first quar­ter of this year, and it needs ad­di­tion­al time to pre­pare its quar­ter­ly fil­ing. Tim­ing on that front was not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER